Researchers reported a bioengineered viral system capable of performing targeted RNA editing in macrophages in vivo, demonstrating therapeutic activity in preclinical sepsis models. Published in Nature Communications, the study uses chemogenetic control to restrict editing activity to immune cells implicated in sepsis pathophysiology. The platform delivers RNA editors via modified viral vectors and shows proof‑of‑concept rescue of dysregulated inflammatory responses in animal models. Authors position the approach as a potential precision intervention for life‑threatening infections where modulating macrophage function could alter disease course. Translation will hinge on safety, delivery specificity and durability of effect.